Clinical Trials for Kidney Cancer

Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Renal Cell Carcinoma

TrialFetch AI summary: Adults with suspected or confirmed metastatic RCC undergoing standard-of-care nephrectomy or metastasectomy receive a percutaneously placed implantable microdevice 72±24 hours pre-op that releases microdoses of up to 19 anticancer agents locally into the tumor to assess in situ drug response; the device and surrounding tissue are removed at surgery. Investigational component is the microdevice-based response profiling (not therapeutic), using FDA-approved or RCC-relevant agents (e.g., TKIs, IO, targeted therapies) to inform sensitivity.

ClinicalTrials.gov ID: NCT05700461

Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic renal cell carcinoma on a stable immune checkpoint inhibitor regimen who develop 1–5 oligoprogressive lesions receive SBRT to all progressing sites (with optional local therapies to some lesions) while continuing the same ICI. Excludes brain-only progression; aims to prolong disease control without switching systemic therapy.

ClinicalTrials.gov ID: NCT04974671

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.

ClinicalTrials.gov ID: NCT06910657

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

TrialFetch AI summary: Adults with metastatic RCC and at least one measurable untreated or locally progressive brain metastasis (asymptomatic/mildly symptomatic, largely steroid-independent; ECOG 0–2) receive nivolumab (PD‑1 inhibitor) plus ipilimumab (CTLA‑4 inhibitor) with cabozantinib (MET/VEGFR/AXL TKI), with maintenance nivolumab/cabozantinib; prior systemic therapy allowed if no prior CTLA‑4, cabozantinib, or MET inhibitor. Primary aim is to improve intracranial PFS; a safety lead-in may omit ipilimumab if excess toxicity.

ClinicalTrials.gov ID: NCT05048212

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

TrialFetch AI summary: Adults with metastatic or unresectable clear cell RCC that is CD70-positive (≥10% by IHC) after progression on at least one ICI and one TKI receive lymphodepletion (fludarabine/cyclophosphamide) followed by a single infusion of allogeneic umbilical cord blood–derived NK cells engineered with a CD70-directed CAR and IL-15, with CRISPR knockout of TGF-β receptor type II to resist TGF-β–mediated immunosuppression. Key exclusions include active infections, autoimmune disease requiring treatment, uncontrolled CNS disease, and significant organ comorbidities.

ClinicalTrials.gov ID: NCT07072234

A Phase 1b Study to Assess the Effects of Belzutifan on 89Zr-DFO-girentuximab Uptake as a Surrogate to Determine CAIX Tumor Expression in Patients With Clear Cell Renal Cell Carcinoma

TrialFetch AI summary: Adults with advanced/metastatic clear cell RCC after progression on prior immune checkpoint therapy (≥2 prior regimens) receive belzutifan monotherapy (HIF‑2α inhibitor) with paired 89Zr‑DFO‑girentuximab PET imaging to assess changes in CAIX expression at 4 weeks. Includes patients with measurable disease, KPS ≥60%, and allows controlled viral infections and stable brain metastases.

ClinicalTrials.gov ID: NCT07179770

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic clear cell renal cell carcinoma or non-small cell lung cancer who had at least stable disease on one prior line of PD-1/PD-L1 therapy but then radiographically progressed within 6 months of stopping it (ECOG 0–1; measurable disease; no active CNS disease or uncontrolled autoimmune disease) and lack/decline standard options. Patients receive retifanlimab (anti–PD-1 antibody) 500 mg IV every 4 weeks as checkpoint rechallenge combined with oral ruxolitinib (JAK1/2 inhibitor) twice daily with dose escalation to define the recommended dose.

ClinicalTrials.gov ID: NCT07219576

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

TrialFetch AI summary: Enrolling adults with ECOG 0–1 and advanced CD70-expressing malignancies needing additional therapy: ccRCC after ≥1 prior line including ICI+TKI, DLBCL/high-grade B-cell lymphoma after ≥2 prior lines including immunochemotherapy and salvage, peripheral T-cell lymphoma after ≥1 systemic therapy, or CTCL (mycosis fungoides/Sézary) stage IIB+ with B0/B1 blood involvement after ≥1 systemic therapy. Participants receive INCA036873 monotherapy, an investigational CD70×CD3 bispecific T-cell engager intended to redirect T cells to kill CD70-positive tumor cells.

ClinicalTrials.gov ID: NCT07195916

A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

TrialFetch AI summary: Adults with locally confirmed IDH1 R132–mutated hematologic malignancies (including AML and MDS) or non-glioma solid tumors who have moderate/severe hepatic impairment or severe renal impairment (with matched adequate-function control cohorts) receive once-daily oral ivosidenib, a mutant IDH1 inhibitor that lowers 2-hydroxyglutarate and promotes differentiation. Azacitidine co-treatment is allowed for hematologic malignancies, and prior/ongoing ivosidenib may be permitted in select cases.

ClinicalTrials.gov ID: NCT07006688